|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
An Exploration of the Determinants that Impact Breast and Cervical Cancer Control
|
1R03CA132550-01
|
$50,000
|
$50,000
|
English, Kevin
|
ALBUQUERQUE AREA INDIAN HEALTH BOARD
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
American Psychosocial Oncology Society 4th Annual Conference
|
1R13CA126310-01
|
$10,000
|
$10,000
|
MCCORKLE, RUTH
|
AMERICAN PSYCHOSOCIAL ONCOLOGY SOCIETY
|
|
An Exploration of Perceived Racial/Ethnic Discrimination in Cancer Care Delivery
|
1R03CA124752-01A1
|
$77,034
|
$77,034
|
Campesino, Maureen
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Investigating intervention opportunities for prostate cancer patients and partner
|
1R03CA128475-01
|
$72,711
|
$72,711
|
COON, DAVID
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
3R01CA182901-04S1
|
$39,254
|
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
Novel Biomarkers for the Clinical Management of Bladder Cancer
|
1R01CA227277-01A1
|
$466,211
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
PROP SENSITIVITY AND OBESITY AMONG ETHNIC CHILDREN
|
5R01CA116766-03
|
$430,666
|
$430,666
|
Baranowski, Tom
|
BAYLOR COLLEGE OF MEDICINE
|
|
Context-Specific Functional Annotation of EGFR Mutations in Glioblastoma
|
5F32CA221015-02
|
$59,038
|
|
KONG, KATHLEEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
2/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education
|
1P20CA221729-01A1
|
$258,006
|
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer
|
1U54CA233223-01
|
$6,353,982
|
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Predictors of Children's Serving Sizes & Mealtime Intake
|
5R01CA107545-03
|
$412,692
|
$330,154
|
Nicklas, Theresa
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$3,566
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$7,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
|
1U01DE028233-01
|
$536,395
|
|
SIKORA, ANDREW
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Target for Chromatin Remodeler Defects in Cancer
|
1R35CA231993-01
|
$594,375
|
|
WALKER, CHERYL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
3R01CA197359-04S1
|
$68,577
|
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Genetics Professional Education in a Global Community of Practice
|
2R25CA171998-06
|
$280,269
|
|
BLAZER, KATHLEEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
7R01CA211614-02
|
$475,560
|
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Yes 2 Success
|
1R25CA233431-01
|
$485,999
|
|
KITTLES, RICK
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs
|
1R21CA232275-01
|
$225,765
|
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$43,250
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combined breast MRI/biomarker strategies to identify aggressive biology
|
3U01CA189283-04S1
|
$190,203
|
|
SEEWALDT, VICTORIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Mentored Clinical Scientist Research Career Development Award (Parent K08)
|
1K08CA234394-01
|
$249,042
|
|
SLAVIN, THOMAS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Refinement of CAR-T-Cell therapy targeting glioblastomas
|
1F99CA234923-01
|
$30,024
|
|
WANG, DONGRUI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Role of Vitamin B5 and Coenzyme A Metabolism in PI3K Driven Tumorigenesis
|
4R00CA194314-03
|
$249,000
|
|
DIBBLE, CHRISTIAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tissue-specific genetic interactions in cancer
|
1R01CA232372-01
|
$505,643
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Spectro-Holographic Instrument for Dynamic Sensing of Cancer Progression
|
1R01CA228029-01A1
|
$688,217
|
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older
|
3R01CA181357-05S1
|
$20,788
|
|
SCHONBERG, MARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Total relevant funding to Basic Behavioral and Social Science for this search: $84,241,007
|